Research ExplorerPublicationsOutcomes of valve-in-valve transcatheter aortic valve implan...

Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture

Standard

Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. / Brinkmann, Christina; Abdel-Wahab, Mohamed; Bedogni, Francesco; Bhadra, Oliver Daniel; Charbonnier, Gaetan; Conradi, Lenard; Hildick-Smith, David; Kargoli, Faraj; Latib, Azeem; Van Mieghem, Nicolas M; Mylotte, Darren; Landes, Uri; Pilgrim, Thomas; Stripling, Jan; Taramasso, Maurizio; Tchétché, Didier; Testa, Luca; Thiele, Holger; Webb, John; Windecker, Stephan; Witt, Julian; Wohlmuth, Peter; Schofer, Joachim.

In: EUROINTERVENTION, Vol. 17, No. 10, 19.11.2021, p. 848-855.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brinkmann, C, Abdel-Wahab, M, Bedogni, F, Bhadra, OD, Charbonnier, G, Conradi, L, Hildick-Smith, D, Kargoli, F, Latib, A, Van Mieghem, NM, Mylotte, D, Landes, U, Pilgrim, T, Stripling, J, Taramasso, M, Tchétché, D, Testa, L, Thiele, H, Webb, J, Windecker, S, Witt, J, Wohlmuth, P & Schofer, J 2021, 'Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture', EUROINTERVENTION, vol. 17, no. 10, pp. 848-855. https://doi.org/10.4244/EIJ-D-21-00254

APA

Brinkmann, C., Abdel-Wahab, M., Bedogni, F., Bhadra, O. D., Charbonnier, G., Conradi, L., Hildick-Smith, D., Kargoli, F., Latib, A., Van Mieghem, N. M., Mylotte, D., Landes, U., Pilgrim, T., Stripling, J., Taramasso, M., Tchétché, D., Testa, L., Thiele, H., Webb, J., ... Schofer, J. (2021). Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. EUROINTERVENTION, 17(10), 848-855. https://doi.org/10.4244/EIJ-D-21-00254

Vancouver

Brinkmann C, Abdel-Wahab M, Bedogni F, Bhadra OD, Charbonnier G, Conradi L et al. Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. EUROINTERVENTION. 2021 Nov 19;17(10):848-855. https://doi.org/10.4244/EIJ-D-21-00254

Bibtex

@article{01b9b56b45e6423190f42d35a4dbe12d,
title = "Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture",
abstract = "BACKGROUND: Bioprosthetic valve fracture (BVF) is a technique to reduce gradients in valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) procedures. The outcome of VIV-TAVI with BVF has not been compared with VIV-TAVI without BVF.AIMS: The aim of this study was to evaluate the outcome of VIV-TAVI with BVF compared to VIV-TAVI without BVF.METHODS: In total, 81 cases of BVF VIV-TAVI (BVF group) from 14 centres were compared to 79 cases of VIV-TAVI without BVF (control group).RESULTS: VARC-2-defined device success was 93% in the BVF group and 68.4% in the control group (p<0.001). The mean transvalvular gradient decreased from 37±13 mmHg to 10.8±5.9 mmHg (p<0.001) in the BVF group and from 35±16 mmHg to 15.8±6.8 mmHg (p<0.001) in the control group with a significantly higher final gradient in the control group (p<0.001). The transvalvular gradients did not change significantly over time. In-hospital major adverse events occurred in 3.7% in the BVF group and 7.6% in the control group (p=0.325). A linear mixed model identified BVF, self-expanding transcatheter heart valves (THVs) and other surgical aortic valve (SAV) types other than Mitroflow as predictors of lower transvalvular gradients.CONCLUSIONS: Compared to VIV-TAVI alone, VIV-TAVI with BVF resulted in a significantly lower transvalvular gradient acutely and at follow-up. Independent predictors of lower gradients were the use of self-expanding THVs and the treatment of SAVs other than Mitroflow, irrespective of BVF performance. BVF significantly reduced the gradient independently from transcatheter or surgical valve type.",
keywords = "Aortic Valve/diagnostic imaging, Aortic Valve Stenosis/diagnostic imaging, Bioprosthesis, Heart Valve Prosthesis, Humans, Prosthesis Design, Prosthesis Failure, Transcatheter Aortic Valve Replacement/adverse effects, Treatment Outcome",
author = "Christina Brinkmann and Mohamed Abdel-Wahab and Francesco Bedogni and Bhadra, {Oliver Daniel} and Gaetan Charbonnier and Lenard Conradi and David Hildick-Smith and Faraj Kargoli and Azeem Latib and {Van Mieghem}, {Nicolas M} and Darren Mylotte and Uri Landes and Thomas Pilgrim and Jan Stripling and Maurizio Taramasso and Didier Tch{\'e}tch{\'e} and Luca Testa and Holger Thiele and John Webb and Stephan Windecker and Julian Witt and Peter Wohlmuth and Joachim Schofer",
year = "2021",
month = nov,
day = "19",
doi = "10.4244/EIJ-D-21-00254",
language = "English",
volume = "17",
pages = "848--855",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "10",

}

RIS

TY - JOUR

T1 - Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture

AU - Brinkmann, Christina

AU - Abdel-Wahab, Mohamed

AU - Bedogni, Francesco

AU - Bhadra, Oliver Daniel

AU - Charbonnier, Gaetan

AU - Conradi, Lenard

AU - Hildick-Smith, David

AU - Kargoli, Faraj

AU - Latib, Azeem

AU - Van Mieghem, Nicolas M

AU - Mylotte, Darren

AU - Landes, Uri

AU - Pilgrim, Thomas

AU - Stripling, Jan

AU - Taramasso, Maurizio

AU - Tchétché, Didier

AU - Testa, Luca

AU - Thiele, Holger

AU - Webb, John

AU - Windecker, Stephan

AU - Witt, Julian

AU - Wohlmuth, Peter

AU - Schofer, Joachim

PY - 2021/11/19

Y1 - 2021/11/19

N2 - BACKGROUND: Bioprosthetic valve fracture (BVF) is a technique to reduce gradients in valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) procedures. The outcome of VIV-TAVI with BVF has not been compared with VIV-TAVI without BVF.AIMS: The aim of this study was to evaluate the outcome of VIV-TAVI with BVF compared to VIV-TAVI without BVF.METHODS: In total, 81 cases of BVF VIV-TAVI (BVF group) from 14 centres were compared to 79 cases of VIV-TAVI without BVF (control group).RESULTS: VARC-2-defined device success was 93% in the BVF group and 68.4% in the control group (p<0.001). The mean transvalvular gradient decreased from 37±13 mmHg to 10.8±5.9 mmHg (p<0.001) in the BVF group and from 35±16 mmHg to 15.8±6.8 mmHg (p<0.001) in the control group with a significantly higher final gradient in the control group (p<0.001). The transvalvular gradients did not change significantly over time. In-hospital major adverse events occurred in 3.7% in the BVF group and 7.6% in the control group (p=0.325). A linear mixed model identified BVF, self-expanding transcatheter heart valves (THVs) and other surgical aortic valve (SAV) types other than Mitroflow as predictors of lower transvalvular gradients.CONCLUSIONS: Compared to VIV-TAVI alone, VIV-TAVI with BVF resulted in a significantly lower transvalvular gradient acutely and at follow-up. Independent predictors of lower gradients were the use of self-expanding THVs and the treatment of SAVs other than Mitroflow, irrespective of BVF performance. BVF significantly reduced the gradient independently from transcatheter or surgical valve type.

AB - BACKGROUND: Bioprosthetic valve fracture (BVF) is a technique to reduce gradients in valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) procedures. The outcome of VIV-TAVI with BVF has not been compared with VIV-TAVI without BVF.AIMS: The aim of this study was to evaluate the outcome of VIV-TAVI with BVF compared to VIV-TAVI without BVF.METHODS: In total, 81 cases of BVF VIV-TAVI (BVF group) from 14 centres were compared to 79 cases of VIV-TAVI without BVF (control group).RESULTS: VARC-2-defined device success was 93% in the BVF group and 68.4% in the control group (p<0.001). The mean transvalvular gradient decreased from 37±13 mmHg to 10.8±5.9 mmHg (p<0.001) in the BVF group and from 35±16 mmHg to 15.8±6.8 mmHg (p<0.001) in the control group with a significantly higher final gradient in the control group (p<0.001). The transvalvular gradients did not change significantly over time. In-hospital major adverse events occurred in 3.7% in the BVF group and 7.6% in the control group (p=0.325). A linear mixed model identified BVF, self-expanding transcatheter heart valves (THVs) and other surgical aortic valve (SAV) types other than Mitroflow as predictors of lower transvalvular gradients.CONCLUSIONS: Compared to VIV-TAVI alone, VIV-TAVI with BVF resulted in a significantly lower transvalvular gradient acutely and at follow-up. Independent predictors of lower gradients were the use of self-expanding THVs and the treatment of SAVs other than Mitroflow, irrespective of BVF performance. BVF significantly reduced the gradient independently from transcatheter or surgical valve type.

KW - Aortic Valve/diagnostic imaging

KW - Aortic Valve Stenosis/diagnostic imaging

KW - Bioprosthesis

KW - Heart Valve Prosthesis

KW - Humans

KW - Prosthesis Design

KW - Prosthesis Failure

KW - Transcatheter Aortic Valve Replacement/adverse effects

KW - Treatment Outcome

U2 - 10.4244/EIJ-D-21-00254

DO - 10.4244/EIJ-D-21-00254

M3 - SCORING: Journal article

C2 - 34031022

VL - 17

SP - 848

EP - 855

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 10

ER -